Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

NCT06982040 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

DRUG: NTQ5082 capsules 100 mg
DRUG: NTQ5082 capsules 200 mg
DRUG: NTQ5082 capsules 300 mg
DRUG: Placebo

Sponsor

Nanjing Chia-tai Tianqing Pharmaceutical